Picard Medical presents Emperor TAH data showing hemodynamic equivalence to SynCardia STAH in vitro and in vivo

Picard Medical, Inc.

Emperor TAH uses identical blood-contacting materials as FDA-approved SynCardia STAH, replaces pneumatic driver with electromechanical system.
In vitro testing at 125 BPM demonstrates Frank-Starling autoregulation and afterload independence equivalent to pneumatic STAH.
First acute porcine implantation (3 models) separated from bypass without complications, delivering stable hemodynamic support.
Emperor TAH designed for full implantability with transcutaneous energy transfer and internal batteries, eliminating driveline.
SynCardia STAH has over 2,100 implants; Emperor aims to provide next-generation fully implantable TAH platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.